Management of Coagulopathy in Decompensated Chronic Liver Disease

Understanding INR in Liver Disease

The American Association for the Study of Liver Diseases (AASLD) states that INR in liver disease reflects decreased synthesis of coagulation factors but does not accurately predict bleeding risk due to the concurrent reduction in anticoagulant proteins, creating a rebalanced hemostatic system 3
The INR scale was specifically designed for monitoring vitamin K antagonist therapy and is not validated for assessing bleeding risk in cirrhosis, as noted by the International Society on Thrombosis and Haemostasis 4
Global tests of hemostasis, such as thrombin generation or viscoelastic tests, better capture the actual hemostatic status of patients with cirrhosis, though they have not been fully clinically validated, according to the AASLD 3

The European Association for the Study of the Liver (EASL) found that FFP transfusion in patients with cirrhosis and prolonged INR frequently does not lead to full normalization of the prothrombin time 1
Ex vivo studies show FFP only minimally improves thrombin generating capacity in patients with cirrhosis, likely because it delivers both pro- and anticoagulant proteins, as reported by the EASL 1
A Cochrane review found no studies demonstrating the efficacy of prophylactic FFP in preventing bleeding in patients with cirrhosis undergoing invasive procedures, highlighting the need for alternative approaches 1

FFP increases blood volume and portal pressure, potentially exacerbating portal hypertension and increasing bleeding risk, as noted by the EASL 1, 5
Transfusion-related acute lung injury is the leading cause of transfusion-related mortality and can be associated with FFP transfusion, with a reported mortality rate, according to the EASL 5
Transfusion-associated circulatory overload occurs in up to 8% of transfusions with a mortality rate of 5-15%, highlighting the need for careful patient selection and monitoring 5
Allergic or anaphylactic reactions to FFP occur at rates of 1:591 to 1:2,184 plasma units transfused, emphasizing the importance of careful transfusion management 5

For patients requiring invasive procedures, viscoelastic testing (TEG/ROTEM) can guide transfusion strategy and has been shown to significantly reduce blood product use (17% vs 100%) without increasing bleeding complications, as reported by the EASL 1
When correction is needed, low-volume cryoprecipitate may be preferred over high-volume FFP, according to the AASLD 3
Prothrombin complex concentrates (PCCs) may be more effective at correcting INR but are not routinely recommended due to potential thrombotic risks, as noted by the EASL 5

The AASLD explicitly states that INR should not be used to gauge bleeding risk among patients with cirrhosis/ACLF, highlighting the need for alternative assessment tools 3
The EASL strongly recommends against correction of prolonged INR with FFP to decrease procedure-related bleeding in patients with cirrhosis, emphasizing the importance of evidence-based practice 1
For patients requiring invasive procedures, less stringent preprocedural coagulation parameters (INR ≤2.0, platelets ≥25 x109/L) have been associated with fewer hemorrhagic complications and decreased preprocedural FFP/platelet administration compared to historical cut-off points, as reported by the British Society of Gastroenterology 6